You have accessJournal of UrologyProstate Cancer: Staging (MP11)1 Sep 2021MP11-16 COMPARISON OF QUANTITATIVE WHOLE-BODY MRI AND BONE SCAN FOR THE PROGNOSIS OF PATIENTS WITH METASTATIC HORMONE-NAïVE PROSTATE CANCER: A PROSPECTIVE STUDY Hiromichi Iwamura, Jun Ito, Shingo Hatakeyama, Yuta Kojima, Takuma Narita, Teppei Okamoto, Naoki Fujita, Kyo Togashi, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Yasuhiro Kaiho, Makoto Sato, and Chikara Ohyama Hiromichi IwamuraHiromichi Iwamura More articles by this author , Jun ItoJun Ito More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Yuta KojimaYuta Kojima More articles by this author , Takuma NaritaTakuma Narita More articles by this author , Teppei OkamotoTeppei Okamoto More articles by this author , Naoki FujitaNaoki Fujita More articles by this author , Kyo TogashiKyo Togashi More articles by this author , Tohru YoneyamaTohru Yoneyama More articles by this author , Hayato YamamotoHayato Yamamoto More articles by this author , Takahiro YoneyamaTakahiro Yoneyama More articles by this author , Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , Yasuhiro KaihoYasuhiro Kaiho More articles by this author , Makoto SatoMakoto Sato More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001984.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To compare the prognostic significance of quantitative whole-body MRI (WB-MRI) and bone scan (BS) in patients with metastatic hormone-naive prostate cancer (mHNPC). METHODS: We prospectively enrolled 22 patients with mHNPC. All the patients underwent WB-MRI and BS at baseline and treated with first-line gonadotropin-releasing hormone-antagonist monotherapy. Total diffusion volume (tDV) was calculated using Attractive BD-Score®. Bone scan index (BSI) was calculated using BONENAVI. The associations between clinical factors including the calculated tumor volume and castration-resistant PC-free survival (CRPC-FS) were evaluated using Kaplan–Meier and Cox-regression analyses. RESULTS: The median age and follow-up periods were 73 years (69-82) and 17 months (12-26), respectively. The median tDV and BSI at baseline were 104.2 mL (71.6-165.4) and 0.44% (0.16-1.70), respectively. Kaplan–Meier analyses showed that high tDV group showed significantly worse CRPC-FS compared with low tDV group (2y; 89% vs 23%, p=0.013), whereas, CRPC-FS in high and low BSI groups were not significantly different (2y; 71% vs 46%, p=0.118). In multivariate analysis, high tDV (≥104.2 mL) was an independent risk factor for CRPC-FS (HR 69.6, p=0.019), however, high BSI (≥0.44%) was not associated with CRPC-FS (HR 1.38, p=0.540). CONCLUSIONS: Our results suggested that prognostic significance of quantitative WB-MRI is superior to that of quantitative BS. Patients with high tDV may be potential candidate for upfront intensive therapy. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e185-e185 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiromichi Iwamura More articles by this author Jun Ito More articles by this author Shingo Hatakeyama More articles by this author Yuta Kojima More articles by this author Takuma Narita More articles by this author Teppei Okamoto More articles by this author Naoki Fujita More articles by this author Kyo Togashi More articles by this author Tohru Yoneyama More articles by this author Hayato Yamamoto More articles by this author Takahiro Yoneyama More articles by this author Yasuhiro Hashimoto More articles by this author Yasuhiro Kaiho More articles by this author Makoto Sato More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement Loading ...